With unprecedented numbers of practices locking out sales reps, pharma companies are being forced to do a better job of engaging HCPs in other ways
Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.
MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.
The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge.
It's not as though pharma marketers didn't see mobile coming. For the past half decade, they've discussed its potential to transform behaviors and relationships within the healthcare ecosystem. Yet now that mobile has arrived, they find themselves torn between caution and exuberance. Larry Dobrow explains
Hysingla ER is ready for the marketplace, just two months after FDA approval.
CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.
The nighttime sleep aid's Twitter account wrote "Sleep LIKE he finally proposed," last week, a sentiment which didn't resonate positively with the feed's followers.
Biogen Idec handed out 250 Fitbits last year to better understand how MS affects patients' mobility, and how its medications hinder disease progression.
AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.
The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.
FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.
Thomas Sack, President and CEO, MRIGlobal
Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.
Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.
The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.
The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.
Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.
A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.
The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.
Marketers may want to dust off plans to create NP-centric materials.
President Barack Obama says personalized medicines need financial support in SOTU Address; Salix explores M&A options; lobbying groups PhRMA and BIO say generic painkillers without abuse-deterrent features should be pulled from shelves.
Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.
Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.
A deal struck by the drugmaker calls for state HIV programs to access its HCV combo, Viekira Pak, at a significant discount.
The ruling stalls generics until at least September.
FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.
CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.
Key trends from the latest Consumer Electronics Show through the eyes of NostaLab's John Nosta
FDA has named Kathleen Uhl as permanent director of the Office of Generic Drugs.
Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.
Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.
Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
Stop trying to sell your edgy work as a TV spot. By finding a backdoor through digital, risky work can often see the light of day, says one ad consultant.
Clinical trials indicate the CTEP works for specific genetic profiles.
Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.
Havas Group has expanded its footprint in Germany, acquiring Bird & Schulte.
The FDA is looking into whether abbreviated risk information is a good idea for DTC.
Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.
Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.
The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.
BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.
"Although the United States represents almost half of the biologics market in terms of revenue and volume, biosimilars growth will be fueled by focusing on the emerging markets, by addressing non-consumption and patient inability to pay for high-priced biologics."
Regeneron/Sanofi PCSK9 meets Phase-III endpoint; Anthem selects Gilead's Harvoni as primary HCV treatment; GSK and Merck about to begin human trials for Ebola vaccine.
A Phase-II study showed the schizophrenia drug performed as well as, but without the weight gain associated with, an older treatment.
AbbVie announced positive interim Phase-III results Thursday for its endometriosis drug elagolix, but one analyst says its commercial impact is likely linked to its effect on patients' bone mineral density.
The specialty biopharma firm says it's hiring new commercial managers after a buying spree.
The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.
Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.
Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen's patient-care model.
The fifth annual Xerox survey of patients and electronic health records shows patients have high expectations for the digital data.
The artwork is meant to inspire debate and donations for vaccinations.
The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.
India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.
Countering Express Scripts' exclusive status for AbbVie's hep.-C entry, CVS/Caremark makes Harvoni and Sovaldi preferred choices on its drug lists.
Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
The drugmaker launched four doses of the blood pressure medication.
Clemson University researchers found that patients are not all that honest with healthcare providers.
Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.
"Technology is evolving in a way that will make your detailing experiences even more meaningful. 2015 will bring in some exciting and innovative products..."
The committee is slated to rule on Sandoz's Zarzio Jan 7.
The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.
A CVS Health/American Council of the Blind collaboration means some visually impaired patients will soon have more engaging prescription labels.
Rebien Soerensen told a Danish paper that he expects to leave his position before 2019.
Severe flu season to test Roche's Tamiflu; Novartis gains nod for psoriasis drug; Amgen and Kite collaborate on immunotherapy.
"Here are some examples of some elegant initiatives from some very smart people to put a substantial stake in the ground toward these rather monumental global [health] efforts."
Click the above link to access the complete Digital Edition of the January 2015 issue of MM&M, with all text, charts and pictures.
Change within a set-in-its-ways industry can be scary—that is, unless you've got the will and bravado to tackle it head-on. Here are the 40 inventors, strategists, advocates and wonks who are challenging, disrupting and otherwise transforming the healthcare business.
At any well-run business meeting, a smartphone is not only disruptive but also signals that its user is less than fully engaged with the business at hand
Is Crestor the new Energizer Bunny?
COO, Publicis Touchpoint Solutions
Mark Friedman, EVP, chief creative officer, Harrison and Starr
We need to help our health systems and healthcare companies function like agile start-ups
Delivering better patient outcomes takes the right economic instruments. Do market-access teams have the right tools at their disposal to make the value-for-money argument?
Adding skills diversity to Purdue's talent base is an important goal
As these 40 standouts show, the industry is ready to move forward
Long the only game in town, health insurers—many have observed—never mastered the art of customer service. But with a host of tech- and service-savvy upstarts making plays for "their" customers, the rules have changed. Sarah Mahoney examines how the new breed of insurers—who mix high tech with high touch—are trying to outflank the establishment
One issue lurking for marketers is the potential elimination of the tax exemption for advertising
In theory, healthcare marketers love the idea of beacons. In practice? Well, nobody's sure whether patients and physicians will be wowed by their utility or turned off by their invasiveness. Barbara Peck offers a Beacons 101 primer
A look at the content that grabbed most reader interest over the past year.
Pop songs about doctors get heavy rotation in BMJ; digital-health investment tally shows doubling in 2014; scientists finger bats as possible Ebola source.
The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.
The cystic fibrosis drug adds approval for treating a 10th gene mutation.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
Nine drugs that promised meaningful advances over existing treatments earned the coveted status from FDA and were approved.
A focus on the existing Yervoy prescribing community could help Bristol-Myers Squibb drive sales of Opdivo past rival Keytruda, one analyst argues.
FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.
FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.
AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.